Adjuvant short XELOX followed by capecitabine for stage III colon cancer : Phase II study / Eman Sobhy Elbanna ; Supervised Mostafa Mahmoud Elserafi , Ghada Mahmoud Sherif , Yahia Mahmoud Ismail

Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology (Medical)

Background: The standard of care for adjuvant chemotherapy for stage III colon cancer is six months of oxaliplatincontaining regimen. Despite its survival benefits; still the cumulative neurotoxicity is a deleterious challenging problem. Aim: Evaluation of the efficacy and toxicity of shorter duration of Oxaliplatin in the adjuvant treatment for stage III colon cancer. Patients & Methods: A prospective single arm phase II study included a total number of 50 patients with resected stage III colon cancer presented to NCI and Tanta cancer center. Patients received adjuvant 3-months of XELOX (Capecitabine and Oxaliplatin) followed by 3 months of single agent Capecitabine. Results: The median age of patients was 43years (range: 21- 70) with male predominance. The majority of patients (70%) had right-sided lesions and N1 stage (64%). After a median follow up period of 36.8 months (range: 9.5-50.8); the 3-year cumulative disease free survival (DFS) & overall survival (OS) were 57.2 &86.3% respectively. Patients{u2019} age, presence of comorbidity, higher grade, development of chemotherapy-related peripheral neuropathy (PN), N2 stage , perineural invasion (PNI) and lymph node ratio (LNR) > 0.25 were significantly associated with worse DFS whereas, the latter two were significantly related to worse OS . Diarrhea, vomiting, hand-foot syndrome and PN were the most common grade 3 toxicity. The latter was significantly higher in patients with preexisting diabetes

Issued also as CD